A PHASE-II STUDY OF CONTINUOUS-INFUSION 5-FLUOROURACIL IN ADVANCED HORMONE-REFRACTORY PROSTATE-CANCER - AN ILLINOIS CANCER CENTER STUDY

被引:0
|
作者
KUZEL, TM [1 ]
TALLMAN, MS [1 ]
SHEVRIN, D [1 ]
BRAUD, E [1 ]
KILTON, L [1 ]
JOHNSON, P [1 ]
KOZLOWSKI, J [1 ]
VOGELZANG, NJ [1 ]
BLOUGH, R [1 ]
BENSON, AB [1 ]
机构
[1] ILLINOIS CANC CTR,CHICAGO,IL
关键词
CONTINUOUS INFUSION; PROSTATE CANCER; CHEMOTHERAPY; 5-FLUOROURACIL;
D O I
10.1002/1097-0142(19930915)72:6<1965::AID-CNCR2820720629>3.0.CO;2-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. 5-Fluorouracil (5-FU) has been previously associated with therapeutic benefit in hormone refractory prostate cancer. However, no previous study has administered 5-FU as a prolonged continuous infusion, which may be the optimal schedule for this cell-cycle specific agent. Methods. Therefore, 25 patients were treated with 5-FU administered as a continuous intravenous infusion at a dose of 1000 mg/m2/day for 5 days every 28 days. Eligibility required disease defined by bidimensionally measurable lesions or evaluable lesions on bone scan or radiograph with elevated serum levels of prostate-specific antigen (PSA), no severe cytopenias, and an Eastern Cooperative Oncology Group performance status less than 3. Prior chemotherapy was not allowed. Dose modifications were specified for mucositis and hematologic toxicity. Results. Eighteen of 22 patients were evaluable for response and toxicity, whereas 4 were evaluable for toxicity alone. Toxicity was significant using this dose and schedule and included episodes of sudden death (one patient), paroxysmal supraventricular tachycardia (one patient), and congestive heart failure (one patient). Other Grade 3 toxicities included stomatitis (two patients) and diarrhea (one patient). Significant myelosuppression did not occur. Objective responses were not observed, but 12 patients experienced stable disease with a median duration of 4 months. Conclusions. Infusional 5-FU can not be recommended for the treatment of advanced hormone refractory prostate cancer.
引用
收藏
页码:1965 / 1968
页数:4
相关论文
共 50 条
  • [31] A PHASE-II STUDY OF KETOCONAZOLE COMBINED WITH WEEKLY DOXORUBICIN IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE-CANCER RESULTS IN A HIGH RESPONSE RATE
    SELLA, A
    AMATO, R
    ELLERHORST, J
    KILBOURN, R
    BUI, C
    LOGOTHETIS, C
    ZUKIWSKI, A
    JOURNAL OF CHEMOTHERAPY, 1993, 5 : 717 - 718
  • [32] PHASE-II STUDY OF 5-FLUOROURACIL BY PROTRACTED INFUSION IN PATIENTS WITH RELAPSING OR REFRACTORY LYMPHOMA
    ROMAGUERA, JE
    SARRIS, AH
    SWAN, F
    YOUNES, A
    MCLAUGHLIN, P
    RODRIGUEZ, MA
    MOORE, DF
    CABANILLAS, F
    BLOOD, 1994, 84 (10) : A647 - A647
  • [33] ETOPOSIDE, LEUCOVORIN AND 5-FLUOROURACIL IN ADVANCED GASTRIC-CANCER - A PHASE-II STUDY
    VANCUTSEM, E
    FILEZ, L
    DEWYSPELAERE, J
    PENNINCKX, F
    JANSSENS, J
    ANTICANCER RESEARCH, 1995, 15 (03) : 1079 - 1080
  • [34] NEGATIVE PHASE-II STUDY WITH CARBOPLATIN AND 5-FLUOROURACIL IN ADVANCED BREAST-CANCER
    PALACIO, I
    BUESA, JM
    DESANDE, L
    CUEVA, JF
    ESTEBAN, E
    ESTRADA, E
    GRACIA, JM
    LACAVE, AJ
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (01) : 242 - 242
  • [35] Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer
    Eklund, John
    Kozloff, Mark
    Vlamakis, Joy
    Starr, Alexander
    Mariott, Margaret
    Gallot, Lilia
    Jovanovic, Borko
    Schilder, Lawrence
    Robin, Erwin
    Pins, Michael
    Bergan, Raymond C.
    CANCER, 2006, 106 (11) : 2459 - 2465
  • [36] Phase II study of topotecan in metastatic hormone-refractory prostate cancer
    Hudes, GR
    Kosierowski, R
    Greenberg, R
    Ramsey, HE
    Fox, SC
    Ozols, RF
    McAleer, CA
    Giantonio, BJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) : 235 - 240
  • [37] PHASE-II PILOT-STUDY WITH CISPLATIN, ETOPOSIDE, AND CONTINUOUS-INFUSION 5-FLUOROURACIL IN METASTATIC NON-SMALL CELL LUNG-CANCER
    LEE, JS
    DHINGRA, HM
    CHIUTEN, DF
    HOLOYE, PY
    JEFFRIES, D
    MURPHY, WK
    UMSAWASDI, T
    NEIDHART, JA
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1987, 10 (06): : 512 - 514
  • [38] PLATINOL (CDDP) AND CONTINUOUS INTRAVENOUS-INFUSION 5-FLUOROURACIL IN REFRACTORY STAGE-IV BREAST-CANCER - A PHASE-II STUDY
    BITRAN, JD
    KOZLOFF, MF
    DESSER, RK
    CANCER INVESTIGATION, 1990, 8 (3-4) : 335 - 338
  • [39] PHASE-II TRIAL OF CONTINUOUS-INFUSION IPROPLATIN (CHIP) AND 5-FLUOROURACIL (5-FU) IN ADVANCED COLORECTAL-CARCINOMA
    PETRELLI, NJ
    CREAVEN, PJ
    HERRERA, L
    MITTELMAN, A
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 23 (01) : 61 - 62
  • [40] CONTINUOUS 5-FLUOROURACIL (5FU) INFUSION IN CARCINOMA OF THE PANCREAS - A PHASE-II STUDY
    HANSEN, R
    QUEBBEMAN, E
    RITCH, P
    CHITAMBAR, C
    ANDERSON, T
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1988, 295 (02): : 91 - 93